U.S. markets closed
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • Dow 30

    34,935.47
    -149.06 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • Russell 2000

    2,226.25
    -13.78 (-0.62%)
     
  • Crude Oil

    73.81
    +0.19 (+0.26%)
     
  • Gold

    1,812.50
    -18.70 (-1.02%)
     
  • Silver

    25.55
    -0.23 (-0.90%)
     
  • EUR/USD

    1.1872
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    1.2390
    -0.0300 (-2.36%)
     
  • GBP/USD

    1.3908
    -0.0050 (-0.35%)
     
  • USD/JPY

    109.6500
    +0.1890 (+0.17%)
     
  • BTC-USD

    41,773.52
    +60.66 (+0.15%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     
  • Oops!
    Something went wrong.
    Please try again later.

J&J Gains On Revising Guidance After Medical Devices Boost In Q2

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Dhirendra Tripathi

Investing.com – Johnson&Johnson (NYSE:JNJ) stock was up 1.2% in Wednesday’s premarket trading as the company raised its full-year guidance for sales and earnings after a robust second quarter.

The company benefited a little from its COVID-19 vaccine and much more from its medical devices business, which boomed as hospitals resumed the medical procedures they had delayed during the pandemic.

The company’s consumer health business grew 10%, pharmaceutical operations 14% while medical devices rose 59%.

The company expects full-year sales of $93.8 billion to $94.6 billion including $2.5 billion-contribution from its COVID-19 vaccine. Discounting the COVID-19 jab, it still translates into growth of 10.5%-11.5%.

Overall annual adjusted diluted earnings per share are seen at $9.60-$9.70.

Second-quarter adjusted diluted EPS came at $2.48 on sales of $23.31 billion. Both numbers were higher than the estimated $2.29 and $22.5 billion, respectively.

The company’s forecast of $2.5 billion in revenue from sales of COVID-19 vaccines is in stark contrast to Pfizer 's (NYSE:PFE) estimation of $26 billion and Moderna 's (NASDAQ:MRNA) $19.2 billion. 

Both companies have said they expect to profit from their vaccines, while J&J has said it will make its shots available on a not-for-profit basis during the pandemic, according to Reuters.

 

Related Articles

Some Hong Kong banks decline mortgages for Evergrande's off-plan projects

Upbeat earnings, recovery optimism lift Wall St futures